南模生物: 关于回购股份集中竞价减持股份计划公告

Buyback and Reduction Plan - The company repurchased a total of 788,912 shares from February 23, 2024, to May 22, 2024, accounting for 1.0119% of the total share capital, aimed at maintaining company value and shareholder rights [1] - The company plans to reduce up to 779,635 shares, not exceeding 1% of the total share capital, through centralized bidding from September 19, 2025, to December 18, 2025 [2][3] - The repurchased shares will be sold within 12 months after the announcement of the buyback results, and if not sold within three years, the untransferred shares will be canceled [1][3] Shareholder Information - The repurchase account holds 2,346,309 shares, representing 3.01% of the total share capital, which will decrease to 1,566,674 shares, or 2.01%, after the planned reduction [4] - The company has not sold any shares from the repurchase account since its listing [2] Financial Impact - The funds recovered from the share reduction will be included in the company's capital reserve and will not significantly impact the company's operations, finances, or future development [4]